BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Allovectin-7: Phase III ongoing

For a fifth time, a DSMB recommended continuation of the single-blind, U.S. Phase III AIMM trial based on a review of safety data. The study, which completed enrollment of 390 chemotherapy-naïve patients in February...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >